Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain function

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,111 result(s) found for: Brain function. Displaying page 2 of 56.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-001119-30 Sponsor Protocol Number: 2B3-101-CR-001 Start Date*: 2011-06-22
    Sponsor Name:to-BBB technologies B.V.
    Full Title: An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma.
    Medical condition: Solid tumors and brain metastases or recurrent malignant glioma, HER2-positive adenocarcinoma of the breast with brain metastases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005647-24 Sponsor Protocol Number: MIA2019/CT/258 Start Date*: 2021-05-10
    Sponsor Name:Melanoma Institute Australia
    Full Title: A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain met...
    Medical condition: melanoma brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001322-54 Sponsor Protocol Number: CS/2018/6632 Start Date*: 2020-06-15
    Sponsor Name:University Hospitals Bristol and Weston NHS Foundation Trust
    Full Title: Carbon Dioxide Insufflation and Brain Protection During Open Heart Surgery: A Randomised Controlled Trial
    Medical condition: Brain injury during open heart valve surgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10067967 Brain injury PT
    21.1 100000004865 10048935 Open heart surgery LLT
    20.0 10029205 - Nervous system disorders 10077808 Mild neurocognitive disorder LLT
    20.0 10047065 - Vascular disorders 10001526 Air embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-014545-83 Sponsor Protocol Number: C10953/3067/ES/MN Start Date*: 2010-02-24
    Sponsor Name:Cephalon Inc.
    Full Title: A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients wi...
    Medical condition: Patients with excessive Sleepiness associated with mild or moderate closed Traumatic Brain Injury (TBI)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060690 Traumatic brain injury LLT
    12.0 10015595 Excessive daytime sleepiness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001166-26 Sponsor Protocol Number: M13-813 Start Date*: 2015-12-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor R...
    Medical condition: Newly diagnosed glioblastoma (GBM) or gliosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006153 Brain tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) IE (Completed) DE (Completed) BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PT (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005044-86 Sponsor Protocol Number: flu2006 Start Date*: 2007-02-07
    Sponsor Name:Roessingh Research and Development
    Full Title: Influence of long-term administration of fluoxetine on cerebral threshold and muscle activity patterns in chronic stroke patients.
    Medical condition: The effect of fluoxetine on brain excitability and muscle activation will be measured in chronic stroke patients (> 6 months after stroke). As secondary measures, also brain activation, phase-synch...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005954-78 Sponsor Protocol Number: 100-059 Start Date*: 2021-10-13
    Sponsor Name:CEA
    Full Title: Exploring P-glycoprotein-mediated efflux transport at the blood-brain barrier as a biomarker of drug-resistance in focal epilepsy
    Medical condition: Investigation in healthy volunteers and epilepsy patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004555-21 Sponsor Protocol Number: ARRAY-818-201 Start Date*: 2019-07-08
    Sponsor Name:Array BioPharma Inc.
    Full Title: A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
    Medical condition: BRAFV600-Mutant Melanoma Brain Metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005442-37 Sponsor Protocol Number: CT200601 Start Date*: 2007-01-08
    Sponsor Name:University Medical Center St Radboud, department of neurology
    Full Title: PITUITARY DAMAGE AFTER TRAUMATIC BRAIN INJURY; Occurrence of growth hormone deficiency at long term follow-up and the beneficial effects of growth hormone substitution on cardiovascular performance...
    Medical condition: isolated growth hormone deficiency after traumatic brain injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001735-49 Sponsor Protocol Number: CTU/2015/174 Start Date*: 2019-07-01
    Sponsor Name:University College London
    Full Title: Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial
    Medical condition: Patients with stroke or other ischaemic brain injury who have antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000768-13 Sponsor Protocol Number: TUD-CoBRIM-067 Start Date*: 2017-11-21
    Sponsor Name:Technische Universität Dresden
    Full Title: An open-label phase II multicenter study of vemurafenib (Zelboraf®) plus cobimetinib (Cotellic®) after radiosurgery in patients with active BRAF-V600-mutant melanoma brain metastases
    Medical condition: patients with active BRAF-V600-mutant melanoma brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: View results
    EudraCT Number: 2008-003349-97 Sponsor Protocol Number: flu2008 Start Date*: 2008-09-18
    Sponsor Name:Roessingh Research&Development
    Full Title: Influence of a single dose of fluoxetine on brain activity during movement observation and execution, muscle activity and motor function in chronic stroke patients
    Medical condition: The objective of this study is to examine the effect of a single dose of fluoxetine and of movement observation on cortical activity in chronic stroke patients (>6 months after stroke). As secondar...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001324-13 Sponsor Protocol Number: 2007CV27 Start Date*: 2007-05-23
    Sponsor Name:Research and Innovation Services, University of Dundee
    Full Title: Does Vitamin D improve markers of vascular health in stroke patients?
    Medical condition: Stroke (Ischaemic and haemorrhagic)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023027 Ischaemic stroke NOS LLT
    9.1 10048863 Hemorrhagic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000678-41 Sponsor Protocol Number: ET19-006 Start Date*: 2019-05-13
    Sponsor Name:Centre Léon Bérard
    Full Title: CABRAMET - A phase 2 study of cabozantinib in renal cell carcinoma (mRCC) with brain metastases
    Medical condition: Metastatic renal cell carcinoma with non locally pre-treated brain metastases, in first line treatment or after one or two prior treatments.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003362-84 Sponsor Protocol Number: FSJD-DIPG-DC Start Date*: 2016-05-18
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: Phase Ib clinical trial on the safety of immunotherapy with autologous dendritic cells primed with lysate allogeneic tumor lines in patients with diffuse intrinsic pontine glioma ( DIPG )
    Medical condition: Diffuse intrinsic pontine glioma (DIPG)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001148-31 Sponsor Protocol Number: Start Date*: 2011-09-13
    Sponsor Name:Imperial College London
    Full Title: A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000070-29 Sponsor Protocol Number: 74668 Start Date*: 2022-09-15
    Sponsor Name:VU University Medical Center
    Full Title: A Proof-of-Concept Study to Explore the Potential Efficacy of Deferiprone in Patients With Pelizaeus-Merzbacher disease (PMD)
    Medical condition: Pelizaeus-Merzbacher disease
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003799-36 Sponsor Protocol Number: Alco-07-06 Start Date*: 2006-09-13
    Sponsor Name:University of Iceland, Dept. Pharmacology
    Full Title: Effects of alcohol on brain function and autonomic nerves
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003817-32 Sponsor Protocol Number: LOLA-Merz:WMDHP39937 Start Date*: 2013-01-08
    Sponsor Name:Imperial College London
    Full Title: Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate
    Medical condition: Hepatic Encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003190-26 Sponsor Protocol Number: RESTART13 Start Date*: 2013-01-14
    Sponsor Name:ACCORD (Academic and Clinical Central Office for Research & Development) [...]
    1. ACCORD (Academic and Clinical Central Office for Research & Development)
    2. ACCORD (Academic and Clinical Central Office for Research & Development)
    Full Title: REstart or STop Antithrombotics Randomised Trial (RESTART)
    Medical condition: Spontaneous Intracerebral Haemorrhage (ICH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10022753 Intracerebral haemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 11:51:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA